Irving Weissman Sells 20,000 Shares of Forty Seven Inc (NASDAQ:FTSV) Stock
Forty Seven Inc (NASDAQ:FTSV) Director Irving Weissman sold 20,000 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $16.22, for a total transaction of $324,400.00. Following the completion of the transaction, the director now owns 1,196,400 shares in the company, valued at $19,405,608. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of FTSV stock opened at $34.66 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.48 and a quick ratio of 7.48. The firm has a market cap of $610.47 million, a PE ratio of -9.24 and a beta of 2.44. The company has a 50-day moving average of $10.74 and a two-hundred day moving average of $9.20. Forty Seven Inc has a 1-year low of $5.53 and a 1-year high of $35.00.
Forty Seven (NASDAQ:FTSV) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.38) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.38). The company had revenue of $15.68 million for the quarter, compared to analyst estimates of $15.80 million. Sell-side analysts anticipate that Forty Seven Inc will post -2.53 EPS for the current fiscal year.
Several analysts have recently weighed in on the stock. Oppenheimer dropped their price target on shares of Forty Seven from $35.00 to $20.00 in a research note on Wednesday, August 14th. Citigroup reaffirmed an “outperform” rating and set a $35.00 price target (up previously from $20.00) on shares of Forty Seven in a research report on Tuesday. Credit Suisse Group reiterated an “outperform” rating and issued a $18.00 price objective (up from $15.00) on shares of Forty Seven in a report on Thursday, December 5th. Guggenheim initiated coverage on Forty Seven in a research report on Wednesday, November 20th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, Roth Capital increased their price objective on Forty Seven from $28.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a sell rating and ten have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $29.55.
About Forty Seven
Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.
See Also: 52 Week Highs
Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.